Document Detail


Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register.
MedLine Citation:
PMID:  20056769     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To evaluate the risk-benefit profile of anti-TNF therapies in PsA and to study the predictors of treatment response and disease remission [disease activity score (DAS)-28 < 2.6].
METHODS: The study included PsA patients (n = 596) registered with the British Society for Rheumatology Biologics Register (BSRBR). Response was assessed using the European League against Rheumatism (EULAR) improvement criteria. Univariate and multivariate logistic regression models were developed to examine factors associated with EULAR response and disease remission using a range of covariates. Poisson regression was used to calculate incidence rate ratios (IRRs) for serious adverse events (SAEs) vs seronegative RA controls receiving DMARDs, adjusting for age, sex and baseline co-morbidity.
RESULTS: At baseline, the mean (s.d.) DAS-28 was 6.4 (5.6). Of the patients, 70.3% were EULAR responders at 12 months. At 6 months, older patients [adjusted odds ratio (OR) 0.97 per year; 95% CI 0.95, 0.99], females (adjusted OR 0.51; 95% CI 0.34, 0.78) and patients on corticosteroids (adjusted OR 0.45; 95% CI 0.28, 0.72) were less likely to achieve a EULAR response. Over 1776.2 person-years of follow-up (median 3.07 per person), the IRR of SAEs compared with controls was not increased (0.9; 95% CI 0.8, 1.3).
CONCLUSIONS: Anti-TNF therapies have a good response rate in PsA, and have an adverse event profile similar to that seen in a control cohort of patients with seronegative arthritis receiving DMARD therapy.
Authors:
Amr A Saad; Darren M Ashcroft; Kath D Watson; Deborah P M Symmons; Peter R Noyce; Kimme L Hyrich;
Related Documents :
22791489 - Two-stage removal of giant fibrovascular polyp of the oesophagus.
22772459 - Usefulness of ultrasonography-proven tenosynovitis to monitor disease activity of a pat...
18028259 - Complications related to blood donation: a population-based study.
22804979 - Fragmented qrs may predict postoperative atrial fibrillation in patients undergoing iso...
22707069 - Surgical technique: lateral retinaculum release in knee arthroplasty using a stepwise, ...
22607109 - A 4-week, dose-ranging study comparing the efficacy, safety and tolerability of latanop...
18798379 - Long-term efficacy and safety of sirolimus-eluting vs bare-metal stents.
8156659 - Complications of limb lengthening. a learning curve.
9665239 - Efficacy of dhe photodynamic therapy for respiratory papillomatosis: immediate and long...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-01-07
Journal Detail:
Title:  Rheumatology (Oxford, England)     Volume:  49     ISSN:  1462-0332     ISO Abbreviation:  Rheumatology (Oxford)     Publication Date:  2010 Apr 
Date Detail:
Created Date:  2010-03-16     Completed Date:  2011-03-11     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  100883501     Medline TA:  Rheumatology (Oxford)     Country:  England    
Other Details:
Languages:  eng     Pagination:  697-705     Citation Subset:  AIM; IM    
Affiliation:
School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized
Antirheumatic Agents / adverse effects*,  therapeutic use*
Arthritis, Psoriatic / drug therapy*
Case-Control Studies
Cohort Studies
Female
Humans
Male
Middle Aged
Questionnaires
Regression Analysis
Severity of Illness Index
Treatment Outcome
Tumor Necrosis Factor-alpha / adverse effects,  antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Antirheumatic Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab; FYS6T7F842/adalimumab
Comments/Corrections
Comment In:
Rheumatology (Oxford). 2010 Sep;49(9):1793-4; author reply 1794   [PMID:  20457729 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports...
Next Document:  Molecular screening for Candida orthopsilosis and Candida metapsilosis among Danish Candida parapsil...